Monday, April 18, 2011

GHLV, Global Health Ventures Inc., GHLV.OB



  GHLV is a specialty pharmaceutical company with expertise in drug delivery and formulation. GHLV has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route.

Sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down.

It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection.

GHLV's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe.
 ghlv
GHLV recently completed the final formulation of X-Excite for the upcoming clinical trials in the United States.
Results of the interim clinical trials in Europe showed GHLV's X-Excite to appear in the blood rapidly and stay for longer time than the brand, Viagra(R). It is believed the longer presence of the drug in the blood may contribute to both buccal (sublingual) absorption and the gastric absorption.

For North American trials, GHLV has modified the formulation slightly to give the maximal buccal absorption.

No comments: